Factor Xa inhibitors are a type of anticoagulant, or blood thinner. They’re a short- and long-term therapy for venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary ...
In 2008, rivaroxaban (Xarelto; Bayer HealthCare) became the first orally administered direct factor Xa inhibitor to be approved for clinical use in the prevention of venous thromboembolism (VTE) after ...
We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexanet, followed by a 2-hour infusion. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback